Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

141. Assertive Community Treatment for Schizophrenia

Assertive Community Treatment for Schizophrenia Assertive Community Treatment (ACT) for Schizophrenia – Society of Clinical Psychology Description ACT is a multidisciplinary team approach to intensive case management in which the team members share a caseload, have a high frequency of patient contact (typically at least once a week), low patient to staff ratios, and provide outreach to patients in the community. ACT teams include psychiatrists as well as other mental health clinicians (...) . Lehman A.F.; Dixon L.B.; Kernan E.; DeForge B.R.; Postrado L.T. A randomized trial of assertive community treatment for homeless persons with severe mental illness. Archives of General Psychiatry , 54:1038-1043, 1997. Scott J.; Dixon L. Assertive community treatment and case management. Schizophrenia Bulletin 21(4):657-68, 1995. Burns B.J.; Santos, A.B. Assertive community treatment: an update of randomized trials. Psychiatric Services , 46:669-675, 1995. Stein LL, Test MA (1980). An alternative

2014 Society of Clinical Psychology

142. Social Skills Training for Schizophrenia

for training schizophrenic patients in illness self-management: A controlled trial. American Journal of Psychiatry , 149:1549-1555, 1992. Wallace, C.J.; Liberman, R,P,; MacKain, S.J.; and Eckman, T.A. Effectiveness and replicability of modules for teaching social and instrumental skills to the severely mentally ill. American Journal of Psychiatry , 149:654-658, 1992. Wallace, C.J., and Liberman, R.P. Social skills training for patients with schizophrenia: A controlled clinical trial. Psychiatry Research (...) Social Skills Training for Schizophrenia Social Skills Training (SST) for Schizophrenia – Society of Clinical Psychology Description SST uses the principles of behavior therapy to teach communication skills, assertiveness skills, and other skills related to disease management and independent living. SST is usually conducted in small groups that are ideally led by two co-therapists. Skills are broken down into several discrete steps. After reviewing the steps of the skill, the therapist models

2014 Society of Clinical Psychology

143. Social Learning/Token Economy Programs for Schizophrenia

Social Learning/Token Economy Programs for Schizophrenia Social Learning/Token Economy Programs for Schizophrenia – Society of Clinical Psychology Description Token economy programs are generally used in long-term care setting such as long-stay inpatient units and residential care settings, but can be adapted for shorter stay and less intensive treatment programs as well. They are comprehensive behavioral programs, based on social learning principles, in which participants receive reinforcers (...) . (2005). The token economy for schizophrenia: Review of the literature and recommendations for future research. Schizophrenia Research . 75 (2-3): 405-416. Clinical Resources Ayllon, T., and Azrin, N.H. The Token Economy : A Motivational System for Therapy and Rehabilitation . Englewood Cliffs, NJ: Prentice Hall, 1968. Paul, G.L., and Lentz, R.J. Psychosocial Treatment of Chronic Mental Patients: Milieu versus Social-learning Programs . Cambridge, MA: Harvard University Press, 1977. Spaulding, W.D

2014 Society of Clinical Psychology

144. Illness Management and Recovery for Schizophrenia

Illness Management and Recovery for Schizophrenia Illness Management and Recovery (IMR) for Schizophrenia – Society of Clinical Psychology Description Illness Management and Recovery (IMR) focuses on teaching illness self-management to persons with serious mental illness. The emphasis is on recovery by helping clients set and pursue personally meaningful goals. IMR combines 1) psychoeducation about mental illness, 2) cognitive-behavioral approaches to medication management, 3) planning (...) for relapse prevention, 4) social skills training to strengthen social support, and 5) coping skills to manage symptoms of mental illness. Each of these 5 elements has been widely studied, but the combination into a single intervention package has only undergone preliminary evaluation. Key References (in reverse chronological order) Mueser, K.T. et. al (2006). The illness management and recovery program: Rationale, development, and preliminary findings. Schizophrenia Bulletin, 32, p S32-S43. Gingerich, S

2014 Society of Clinical Psychology

145. Cognitive Remediation for Schizophrenia

Cognitive Remediation for Schizophrenia Cognitive Remediation for Schizophrenia – Society of Clinical Psychology Description Cognitive functions such as executive function, learning & memory, processing speed, and sustained attention are frequently impaired and play an important role in the functional impairments seen in schizophrenia. Cognitive remediation (CR) or cognitive rehabilitation interventions are designed to improve cognitive function through repeated practice of cognitive tasks (...) and / or strategy training. CR interventions are typically time-limited. They can be conducted individually or in groups. Some involve extensive use of computers while others focus primarily on paper-and-pencil tasks. Most CR interventions take into account the motivational and emotional deficits that are often present in schizophrenia as well. The goal of CR is to improve cognitive function. Research has shown small to medium effects of CR on neuropsychological measures of cognition, but whether

2014 Society of Clinical Psychology

146. Cognitive Behavioral Therapy for Schizophrenia

psychotic symptoms in schizophrenic patients: I. Outcome. British Journal of Psychiatry , 162: 524-32, 1993. Clinical Resources Kingdon, D.G. & Turkington, D. (2005). Cognitive Therapy of Schizophrenia. Guilford, New York. Chadwick, P., Birchwood, M.J., & Trower, P. (1999). Cognitive Therapy for Delusions, Voices and Paranoia (Wiley Series in Clinical Psychology). Wiley. Kingdon, D.G. & Turkington, D. (1994). Cognitive-Behavioral Therapy of Schizophrenia. Guilford Press, New York. Training Opportunities (...) Cognitive Behavioral Therapy for Schizophrenia Cognitive Behavioral Therapy (CBT) for Schizophrenia – Society of Clinical Psychology Description Similar to Cognitive-Behavioral Therapy (CBT) for other types of problems, CBT for schizophrenia involves establishing a collaborative therapeutic relationship, developing a shared understanding of the problem, setting goals, and teaching the person techniques or strategies to reduce or manage their symptoms. Therapy is usually conducted in individual

2014 Society of Clinical Psychology

147. Supported Employment for Schizophrenia

Supported Employment for Schizophrenia Supported Employment for Schizophrenia – Society of Clinical Psychology Description Supported Employment (SE; also known as Individual Placement and Support) is an approach to vocational rehabilitation (VR) adapted for individuals with serious mental illness. Supported employment emphasizes the integration of employment and mental health services, rapid placement of individuals into jobs in the community, individualized job development, and ongoing job (...) supports. Rather than segregating vocational rehabilitation and mental health services, supported employment specialists are part of the client’s treatment team. The goal of supported employment is to assist the person with schizophrenia in attaining competitive, community-based employment. As compared to more traditional VR approaches for this population (e.g. clubhouse models, transitional employment), the community-based nature of SE facilitates transfer of skills into real-world work settings

2014 Society of Clinical Psychology

148. Psychosis and schizophrenia in adults: prevention and management

Psychosis and schizophrenia in adults: prevention and management Psy Psychosis and schizophrenia in adults: chosis and schizophrenia in adults: pre prev vention and management ention and management Clinical guideline Published: 12 February 2014 nice.org.uk/guidance/cg178 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view (...) in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Psychosis and schizophrenia in adults: prevention and management (CG178) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions

2014 National Institute for Health and Clinical Excellence - Clinical Guidelines

149. Schizophrenia: lurasidone

Schizophrenia: lurasidone Schizophrenia: lur Schizophrenia: lurasidone asidone Evidence summary Published: 23 September 2014 nice.org.uk/guidance/esnm48 pathways This advice replaces ESNM15. K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in September 2014. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary Lurasidone (Latuda, Sunovion (...) Pharmaceuticals Europe Ltd) is licensed for treating schizophrenia in adults aged 18 years and over. It was launched in the UK in August 2014. Evidence from 5 short- term and 3 long-term studies suggests that lurasidone is effective at treating psychotic symptoms, and at preventing relapse in adults with schizophrenia. The European Public Assessment Report [EPAR] for lurasidone states that the adverse event profile of lurasidone is similar to that for other second-generation antipsychotics, the most common

2014 National Institute for Health and Clinical Excellence - Advice

150. Schizophrenia: aripiprazole prolonged-release suspension for injection

Schizophrenia: aripiprazole prolonged-release suspension for injection Schizophrenia: aripipr Schizophrenia: aripiprazole prolonged-release azole prolonged-release suspension for injection suspension for injection Evidence summary Published: 26 March 2014 nice.org.uk/guidance/esnm39 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in March 2014. See summaries of product characteristics (SPCs), British national formulary (...) (BNF) or the MHRA or NICE websites for up-to-date information. Summary Aripiprazole prolonged-release suspension for injection is licensed for maintenance treatment of schizophrenia in adults whose condition has been stabilised with oral aripiprazole. It was launched in the UK in January 2014. In 2 double-blind, randomised controlled trials (RCTs; n=403 and n=662), once-monthly aripiprazole 400 mg prolonged-release injection was shown to be superior to placebo and non-inferior to oral aripiprazole

2014 National Institute for Health and Clinical Excellence - Advice

151. Community-based intervention for people with schizophrenia successfully provided by supervised community health workers in a low-resource setting

Community-based intervention for people with schizophrenia successfully provided by supervised community health workers in a low-resource setting Community-based intervention for people with schizophrenia successfully provided by supervised community health workers in a low-resource setting | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about (...) how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Community-based intervention for people with schizophrenia successfully provided by supervised

2014 Evidence-Based Mental Health

152. Paliperidone depot is not different from haloperidol in relapse prevention of schizophrenia, but different side effects should be considered

Paliperidone depot is not different from haloperidol in relapse prevention of schizophrenia, but different side effects should be considered Paliperidone depot is not different from haloperidol in relapse prevention of schizophrenia, but different side effects should be considered | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Paliperidone depot is not different from haloperidol in relapse prevention of schizophrenia, but different

2014 Evidence-Based Mental Health

153. Among untreated violent offenders with schizophrenia, persecutory delusions are associated with violent recidivism

Among untreated violent offenders with schizophrenia, persecutory delusions are associated with violent recidivism Among untreated violent offenders with schizophrenia, persecutory delusions are associated with violent recidivism | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Among untreated violent offenders with schizophrenia, persecutory delusions are associated with violent recidivism Article Text Causes and risk factors Among untreated

2014 Evidence-Based Mental Health

154. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. Full Text available with Trip Pro

Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. Long-acting injectable antipsychotics are used to reduce medication nonadherence and relapse in schizophrenia-spectrum disorders. The relative effectiveness of long-acting injectable versions of second-generation and older antipsychotics has not been assessed.To compare the effectiveness of the second-generation long-acting injectable antipsychotic (...) paliperidone palmitate with the older long-acting injectable antipsychotic haloperidol decanoate.Multisite, double-blind, randomized clinical trial conducted from March 2011 to July 2013 at 22 US clinical research sites. Randomized patients (n = 311) were adults diagnosed with schizophrenia or schizoaffective disorder who were clinically assessed to be at risk of relapse and likely to benefit from a long-acting injectable antipsychotic.Intramuscular injections of haloperidol decanoate 25 to 200 mg

2014 JAMA Controlled trial quality: predicted high

155. Case control study: People with schizophrenia are more likely to have a mother who smoked during pregnancy than people without the condition Full Text available with Trip Pro

to genetic factors, environmental factors may play a role in the aetiology of psychotic disorders, and PTE has been considered as having a potential influence on developing psychotic disorders. In the current study, Stathopoulou and colleagues examined the association between prenatal smoking behaviours of mothers of schizophrenic and non-schizophrenic patients. The purpose of their study was to determine if there was an association between PTE and the risk of schizophrenia and the severity (...) of schizophrenic symptomatology. Methods Between 2002 and 2008, 212 schizophrenic inpatients and outpatients were recruited into the study. Diagnoses were determined from a structured clinical interview. A further 212 individuals were included as controls. Control subjects were matched on sex, age, educational level and place of residence. PTE was assessed retrospectively by asking both parents about smoking during pregnancy. Statistical analyses of the data included testing reliability of the schizophrenia

2014 Evidence-Based Nursing

156. Metformin for weight loss in schizophrenia: safe but not a panacea

Metformin for weight loss in schizophrenia: safe but not a panacea Metformin for weight loss in schizophrenia: safe but not a panacea | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin for weight loss in schizophrenia: safe but not a panacea Article Text Pharmacological interventions Metformin for weight loss in schizophrenia: safe but not a panacea Cenk Tek 1 , Lydia Chwastiak 2 Statistics from Altmetric.com What is already

2014 Evidence-Based Mental Health

157. Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines

for schizophrenia: clinical evidence and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions One systematic review and six randomized controlled trials were identified regarding the use of 5HT3 antagonists for the treatment of schizophrenia. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Schizophrenia; Schizophrenic Psychology; Serotonin 5-HT3 Receptor Antagonistss Language Published English Country (...) Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Long-term 5HT3 antagonist use

2014 Health Technology Assessment (HTA) Database.

158. Lurasidone - Schizophrenia

Lurasidone - Schizophrenia Common Drug Review CDEC Meeting — November 21, 2012; CDEC Reconsideration — January 16, 2013 Notice of CDEC Final Recommendation — January 23, 2013 Page 1 of 5 © 2013 CADTH FINAL CDEC RECOMMENDATION LURASIDONE (Latuda — Sunovion Pharmaceuticals Canada Inc.) Indication: Acute Treatment of Schizophrenia Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that lurasidone not be listed. Reason for the Recommendation: There is insufficient evidence from (...) randomized controlled trials (RCTs) to establish the comparative efficacy of lurasidone relative to other less costly antipsychotics for the acute treatment of schizophrenia. Background: Lurasidone (Latuda) is an atypical antipsychotic with a Health Canada indication for the acute treatment of schizophrenia. Lurasidone is available in 40 mg, 80 mg, and 120 mg film-coated tablets. The product monograph recommends a starting dose of 40 mg once daily and states that patients should be treated

2014 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

159. Effectiveness of a community-based intervention for people with schizophrenia and their caregivers in India (COPSI): a randomised controlled trial. Full Text available with Trip Pro

Effectiveness of a community-based intervention for people with schizophrenia and their caregivers in India (COPSI): a randomised controlled trial. Observational evidence suggests that community-based services for people with schizophrenia can be successfully provided by community health workers, when supervised by specialists, in low-income and middle-income countries. We did the COmmunity care for People with Schizophrenia in India (COPSI) trial to compare the effectiveness of a collaborative (...) community-based care intervention with standard facility-based care.We did a multicentre, parallel-group, randomised controlled trial at three sites in India between Jan 1, 2009 and Dec 31, 2010. Patients aged 16-60 years with a primary diagnosis of schizophrenia according to the tenth edition of the International Classification of Diseases, Diagnostic Criteria for Research (ICD-10-DCR) were randomly assigned (2:1), via a computer-generated randomisation list with block sizes of three, six, or nine

2014 Lancet Controlled trial quality: predicted high

160. Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia. (Abstract)

Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia. Treatment of schizophrenia depends heavily on neuroleptic drugs. Hypersalivation is a common side effect when people with schizophrenia are treated with neuroleptic drugs. Hypersalivation can be an embarrassing and stigmatising problem, can affect quality of life and can result in discontinuation of neuroleptic treatment. It can also be difficult to treat.To summarise the best (...) available evidence of the effects of anticholinergic drugs in the treatment of non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia. Clozapine-induced hypersalivation has been addressed in another Cochrane review.We searched the Cochrane Schizophrenia Group Trials Register (15 November 2012) and inspected references of all identified studies for further relevant studies. We were to contact the first author of each included study for information regarding unpublished trials.All

2013 Cochrane